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Dr. Guan Chen previously worked in Sun Yat-sen University and German cancer research Center as well in Dana-Farber focused on investigating on biochemical mechanisms involved in cancer drug response by discovering Thaliblastine as a novel and non-toxic p-glycoprotein inhibitor to reverse multiple drug resistance (*Cancer Res* 1993;53:2544-7,) and nonpolyglutamatable antifolates as new analogues to reverse the resistance (*Mol Pharmacol* 1995;48:758-65).

Dr. Guan Chen took a first faculty position to study Oncogene signaling and cancer therapeutic development in Lerner Research Institute, Cleveland Foundation. During this period, his first major discovery was that normal cellular Kras, but not Nras and Hras, is required for normal diploid cell proferation. Then, his work further found that oncogene including Ras can directly activate expression of DNA-topoisomerase II, thus direct linking oncogene activation and cancer therapeutic target overexpression. Most significantly, Dr. Chen found that Ras-activated p38 MAPK is a negative feedback to inhibit Ras proliferative activity.

Dr, Guan Chen worked as a tenured associate professor from 09/2000 to 02/2006. During this period, his laboratory found that there is a stress pathway from JNK and p38 that can activate *VDR* gene transcription. Moreover, his laboratory found that p38 isoform proteins can be opposite in regulating gene expression and stress response, estrogen receptor and vitamin D receptor can suppress stress-induced cell death by binding c-Jun and inhibiting its activity. Most importantly, Dr. Chen׳s work discovered that a p38g MAPK is activated by Kras oncogene in intestinal epithelial cells and silencing p38g expression suppress Kras transformation independent phosphorylation.

Dr. Guan Chen from 03/2006 has worked as a tenured Professor in Department of Pharmacology and Toxicology, at Medical College of Wisconsin. He identified a novel phosphatase PTPH1 that cooperates with p38*γ* to promote Kras transformation. Moreover, he showed that p38g is a triple-negative breast cancer oncogene in breast cancer and p38*γ* is required for inflammation-induced colon cancer in mice. Recently, his mouse genetic work further demonstrated the oncogenic activity of p38*γ* and PTPH1 in colon cancer, pancreatic cancer and breast cancer.

Dr. Guan Chen׳s research work has been continuously supported by NIH and/or VA and/or DOD and Medical College of Wisconsin for 18 years, with total of more than 60 original publications in top-tier journals such as *Cancer Res*., *Oncogene*, *JBC* and *Stem Cells*. Dr. Guan Chen is now serving as editorial board for journals including *Acta Pharmaceutica Sinica B*, *Journal of Cancer Therapeutics* and Research and American Journal of Cancer Res, etc., and has served as *ad hoc* reviewer for *PNAS*, *Cancer Res*, *Oncogene*, *Blood*, *Cell Res*, and *Clin Cancer Res,* et al.
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Dr. Wei Li is a tenured professor in the Department of Pharmaceutical Sciences, College of Pharmacy, the University of Tennessee Health Science Center (UTHSC). Dr. Li received his Bachelor׳s degree in Chemical Physics from the University of Science and Technology of China in 1992. After a short graduate student at the Dalian Institute of Chemical Physics, an institute of the Chinese Academy of Sciences, he continued his graduate study in Columbia University and received his Ph.D. in Chemistry in 1999, before he started as a faculty member in his current institution. He is currently a Professor, the Director of the UTHSC College of Pharmacy Drug Discovery Center, and the Faculty Director of the Shared Analytical Instrument Facility.

Dr. Li׳s research is focused on developing small molecules for cancer and inflammation, using medicinal chemistry approaches. Currently he is working on three major projects. One project is to develop a new generation of tubulin inhibitors targeting the colchicine binding site that: (1) are orally bioavailable to avoid the intravenous administration; (2) effectively overcome several clinically relevant multiple drug resistance associated with the prolonged administration of existing tubulin inhibitors; and (3) have significantly improved safety profiles and thus higher therapeutic indexes than existing tubulin inhibitors. The current lead compound developed from this project has been licensed by Veru Healthcare as the clinical candidate VERU-111 for clinical trials which is scheduled to start in late 2018.

The second project is to develop noncalcemic vitamin D analogs as a potential treatment for autoimmune diseases, currently focusing on rheumatoid arthritis. While vitamin D itself has shown a number of beneficial biological activities against cancer and inflammation besides its classical role in maintaining calcium homeostasis, its clinical application is limited by its severe hypercalcemic side effects at therapeutic doses. Dr. Li׳s biological collaborators have recently discovered new metabolic pathways of vitamin D that generate 20-hydroxyvitamin D related metabolites. Dr. Li׳s laboratory has subsequently synthesized many of these bioactive metabolites and their non-natural analogs. Some of these new vitamin D analogs has strong efficacy against inflammation in preclinical studies and are not hypercalcemia well above their therapeutic doses. The development of these compounds holds great potential not only for rheumatoid arthritis, but also for other autoimmune diseases.

The third project is to develop selective small molecule inhibitors for Inhibitors of Apoptotic Proteins (IAPs). Through an *in silico* virtual screening efforts followed by biological validations, Dr. Li׳s laboratory has discovered a small molecule scaffold that show selective inhibition of IAPs. He is currently working on to further optimizing the molecular structures in this scaffold.

Dr. Li is an inventor of five issued US patents, a large number of derived patents from other countries, and several non-provisional patent applications. He has published over 140 peer-reviewed papers and is a frequent grant reviewer for NIH and several funding agencies from both US state government and foreign countries.
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